Literature DB >> 10901363

Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers.

R Gershoni-Baruch1, Y Patael, A Figer, L Kasinetz, E Kadouri, R Bruchim Bar Sade, E Friedman.   

Abstract

The frequency of the APC I1307K mutation and its association with disease pattern was examined in 996 Ashkenazi women consisting of individuals with either sporadic (n = 382) or hereditary (n = 143) breast and/or ovarian cancer; asymptomatic BRCA1/2 mutation carriers (185delAG, 5382insC and 6174delT) (n= 53) and healthy controls (n= 418). The I1307K allele was equally distributed among women with sporadic (17/382; 4.6%) and inherited (10/143; 7%) breast and/or ovarian cancer irrespective of their being diagnosed before or after 42 years of age and among asymptomatic (7/53; 13.2%) and cancer manifesting BRCA1/2 carriers (10/143; 7%). Taken together, the prevalence of the I1307K allele was significantly higher in BRCA1/2 carriers compared to non-BRCA1/2 carriers (17/196; 8.7% and 40/800, 5%; respectively). The high prevalence of the I1307K allele among BRCA1/2 carriers is not associated with increased cancer risk but seems to be genetically connected because of Jewish ancestry.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901363      PMCID: PMC2363478          DOI: 10.1054/bjoc.2000.1248

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Common origin of the I1307K APC polymorphism in Ashkenazi and non-Ashkenazi Jews.

Authors:  Y Patael; A Figer; R Gershoni-Baruch; M Z Papa; S Risel; R Shtoyerman-Chen; A Karasik; L Theodor; E Friedman
Journal:  Eur J Hum Genet       Date:  1999-07       Impact factor: 4.246

2.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Authors:  D Abeliovich; L Kaduri; I Lerer; N Weinberg; G Amir; M Sagi; J Zlotogora; N Heching; T Peretz
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

Review 3.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.

Authors:  P Tonin; B Weber; K Offit; F Couch; T R Rebbeck; S Neuhausen; A K Godwin; M Daly; J Wagner-Costalos; D Berman; G Grana; E Fox; M F Kane; R D Kolodner; M Krainer; D A Haber; J P Struewing; E Warner; B Rosen; C Lerman; B Peshkin; L Norton; O Serova; W D Foulkes; J E Garber
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

4.  Sequence-determined DNA separations.

Authors:  L S Lerman; S G Fischer; I Hurley; K Silverstein; N Lumelsky
Journal:  Annu Rev Biophys Bioeng       Date:  1984

5.  Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.

Authors:  S Neuhausen; T Gilewski; L Norton; T Tran; P McGuire; J Swensen; H Hampel; P Borgen; K Brown; M Skolnick; D Shattuck-Eidens; S Jhanwar; D Goldgar; K Offit
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

6.  Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis.

Authors:  E M Rohlfs; W G Learning; K J Friedman; F J Couch; B L Weber; L M Silverman
Journal:  Clin Chem       Date:  1997-01       Impact factor: 8.327

7.  High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer.

Authors:  B Modan; E Gak; R B Sade-Bruchim; G Hirsh-Yechezkel; L Theodor; F Lubin; G Ben-Baruch; U Beller; A Fishman; R Dgani; J Menczer; M Papa; E Friedman
Journal:  JAMA       Date:  1996-12-11       Impact factor: 56.272

8.  Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.

Authors:  L S Friedman; C I Szabo; E A Ostermeyer; P Dowd; L Butler; T Park; M K Lee; E L Goode; S E Rowell; M C King
Journal:  Am J Hum Genet       Date:  1995-12       Impact factor: 11.025

9.  Aberrations of the APC gene in primary breast carcinoma.

Authors:  M Kashiwaba; G Tamura; M Ishida
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer.

Authors:  A M Thompson; R G Morris; M Wallace; A H Wyllie; C M Steel; D C Carter
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more
  6 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.

Authors:  Emily P Slater; Peter Langer; Volker Fendrich; Nils Habbe; Brunhilde Chaloupka; Elvira Matthäi; Mercedes Sina; Stephan A Hahn; Detlef K Bartsch
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

3.  EMSY promoted the growth and migration of ovarian cancer cells.

Authors:  Xiaohong Zhao; Yan Zhou; Mingchao Nie; Saiqiong Xian; Huli Chen; Yingmei Wen; Linjing Zhang; Yumin Huang; Mingfa Chen; Shaosheng Wang
Journal:  Tumour Biol       Date:  2014-12-16

4.  Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer.

Authors:  Xianshu Wang; Ellen L Goode; Zachary S Fredericksen; Robert A Vierkant; V Shane Pankratz; Wen Liu-Mares; David N Rider; Celine M Vachon; James R Cerhan; Janet E Olson; Fergus J Couch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

5.  An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population.

Authors:  Adrianna Mostowska; Piotr Pawlik; Stefan Sajdak; Janina Markowska; Monika Pawałowska; Margarita Lianeri; Paweł P Jagodzinski
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

Review 6.  Wnt/β-catenin signalling in ovarian cancer: Insights into its hyperactivation and function in tumorigenesis.

Authors:  Vu Hong Loan Nguyen; Rebecca Hough; Stefanie Bernaudo; Chun Peng
Journal:  J Ovarian Res       Date:  2019-12-11       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.